(Q39651800)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339450%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

title

Therapeutic drug monitoring of imatinib: Bayesian and alternative methods to predict trough levels (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339450%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339450%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Nicolas Widmer

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339450%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Laurent Arthur Decosterd

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339450%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Chantal Csajka

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339450%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

author name string

Michael Montemurro

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339450%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Serge Leyvraz

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339450%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Amina Haouala

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339450%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Thierry Buclin

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339450%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

publication date

1 March 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339450%20AND%20SRC:MED&resulttype=core&format=json

Clinical Pharmacokinetics

23 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339450%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

volume

51

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339450%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339450%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

page(s)

187-201

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339450%20AND%20SRC:MED&resulttype=core&format=json

Therapeutic drug monitoring of cancer chemotherapy.

23 January 2020

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11596990-000000000-00000

Adaptive control methods for the dose individualisation of anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596990-000000000-00000

Individualised cancer chemotherapy: strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596990-000000000-00000

Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596990-000000000-00000

Moving towards dose individualization of tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596990-000000000-00000

Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596990-000000000-00000

Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596990-000000000-00000

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596990-000000000-00000

Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596990-000000000-00000

Imatinib and Panax ginseng: a potential interaction resulting in liver toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596990-000000000-00000

Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596990-000000000-00000

Pharmacokinetic resistance to imatinib mesylate: role of the ABC drug pumps ABCG2 (BCRP) and ABCB1 (MDR1) in the oral bioavailability of imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596990-000000000-00000

Clinical pharmacokinetics of imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596990-000000000-00000

Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596990-000000000-00000

Imatinib plasma levels: correlation with clinical benefit in GIST patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596990-000000000-00000

Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596990-000000000-00000

Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596990-000000000-00000

Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596990-000000000-00000

Relationship of serum imatinib trough level and response in CML patients: long term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596990-000000000-00000

Integrating pharmacogenetics and therapeutic drug monitoring: optimal dosing of imatinib as a case-example.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596990-000000000-00000

Drug monitoring of imatinib levels in patients undergoing therapy for chronic myeloid leukaemia: comparing plasma levels of responders and non-responders

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596990-000000000-00000

Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596990-000000000-00000

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596990-000000000-00000

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596990-000000000-00000

NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596990-000000000-00000

A therapeutic drug monitoring algorithm for refining the imatinib trough level obtained at different sampling times

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596990-000000000-00000

Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596990-000000000-00000

Forecasting individual pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596990-000000000-00000

Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596990-000000000-00000

Some suggestions for measuring predictive performance

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596990-000000000-00000

Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596990-000000000-00000

Population pharmacokinetics and pharmacogenetics of imatinib in children and adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596990-000000000-00000

Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596990-000000000-00000

Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596990-000000000-00000

The importance of modeling interoccasion variability in population pharmacokinetic analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596990-000000000-00000

Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596990-000000000-00000

Tyrosine kinase inhibitors concentration monitoring in chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596990-000000000-00000

Who is in charge of assessing therapeutic drug monitoring? The case of imatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596990-000000000-00000

Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596990-000000000-00000

Exposure-response relationships in patients with metastatic renal cell carcinoma receiving sunitinib: maintaining optimum efficacy in clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596990-000000000-00000

Pharmacokinetics and pharmacodynamics of nilotinib in gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596990-000000000-00000

Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596990-000000000-00000

Pharmacokinetic-Pharmacodynamic Relationships of Imatinib and Its Main Metabolite in Patients with Advanced Gastrointestinal Stromal Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596990-000000000-00000

Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients

21 January 2018

1 reference

12 December 2020

Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect

1 reference

12 December 2020

Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia

1 reference

12 December 2020

Guidance for industry on Population Pharmacokinetics; availability. Food and Drug Administration, HHS. Notice

1 reference

12 December 2020